Published: 2021-12-28

Study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis of the knee

Shashikala Eda


Background: Osteoarthritis (OA) of the knee is the most common degenerative joint disorder that results in disability and increased morbidity. Conventional treatment of OA with non-steroidal anti-inflammatory drugs (NSAIDs) often leads to serious adverse side effects that may increase morbidity and mortality. Glucosamine and Methylsulfonylmethane (MSM) have anti-inflammatory and analgesic properties which may supplement NSAIDs. Hence this study was aimed to determine the effectiveness and safety of these drugs in the management of knee OA

Methods: 76 (63.33%) female and 44 (36.67%) male patients of OA of the knees were divided equally into four groups depending upon the therapy with Glucosamine or MSM or their combination (study groups) or none of them (control group) for 12 weeks. After the written consent, a detail Clinical History& Examination, Biochemical investigations, X-rays of chest and knees and ECG were done. The outcome of the treatment was assessed by Western Ontario and McMaster University Osteoarthritis (WOMAC) Index and for any adverse drug effects.

Results: After 12 weeks of study there was significant decrease in mean WOMAC pain scores (27.29-39.13) and total aggregate scores (23.53-37.14%) in study groups (p<0.01-p<0.001) as compared to control group (14.28 % and 8.82% respectively). Besides the relief of pain and improvement in physical functions were superior in patients treated with combination therapy.

 Conclusions: This study showed Glucosamine & MSM are effective in the management of OA of knee and are safe health supplement to NSAIDs while their combination was more superior and effective. 


Joint pains, Physical function, Efficacy, Adverse effects

Full Text:



Silman AJ, Hochberg MC. Epidemiology of the Rheumatic Diseases. 2nd ed. Oxford: Oxford University Press; 2001.

Miller KL, Clegg DO. Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am. 2011;37(1):103-18.

Lawrence RC, Felson DT, Helmick C. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(26):56-6.

Akinpelu AO, Alonge TO, Adekanla BA, Odole AC. Prevalence and pattern of symptomatic knee osteoarthritis in Nigeria: A community-based study. Internet J Allied Health Sci Pract. 2009;7:3.

Solomon L, Beighton P, Lawrence JS. Rheumatic disorders in the South African Negro. Part II. Osteo-arthrosis. S Afr Med J. 1975;49:1737-40.

Davis MA, Ettinger WH, Neuhaus JM, Hauck WW. Sex differences in osteoarthritis of the knee. The role of obesity. Am J Epidemiol. 1988;127:1019-30.

Symmons D, Mathers C, Pfleger B. Global Burden of Osteoarthritis in year 2000: Global burden of disease 2000 study, World health report. 2002;(5):2.

Pal CP, Singh P, Chaturvedi S, Pruthi KK, Ashok V. Epidemiology of knee osteoarthritis in India and related factors. Ind J Orth. 2016;50(5):518-22.

Setnikar I. Antireactive properties of ‘chondroprotective’ drugs.Int J Tissue React. 1992;14:253-61.

Noack W, Fischer M, Firster K. Glucosamine sulphate in steoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:2351-9.

Reichelt A, Forster KK, Fischer M. Efficacy and safety of intramuscular glucosamine sulphate in osteoarthritis of the knee. Arzeimittel Forschung. 1994;44 (1):75-80.

Evans MS, Reid KH, Sharp Jr JB. Dimethylsulfoxide (DSMO) blocks conduction in peripheral nerve C fibres: a possible mechanism of analgesia. Neurosci Lett. 1993;150:145-8.

Zuckner J, Uddin J, Ganter Jr GE. Local application of dimethylsulfoxide, DMSO combined with triamcinolone acetonide in rheumatoid arthritis. Ann N Y Acad Sci. 1967;141:555-9.

Kellgren JH, Lawrence JS. Atlas of standard radiographs. Vol. 2. Oxford: Blackwell Scientific; 1963.

Altman R, Asch E, Bloch D. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29(8):1039-49.

Bellamy N, Buchanan WW, Goldsmith CH. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-40.

Andri MT, Lubis, Siagian C, Wonggokusuma E, Marsetio AF, Setyohadi B. Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial. Acta Med Indones - Indones J Intern Med. 2017;49(2);105-11.

Usha PR, Naidu M. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest. 2004;24(6):376-81.

Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin. 1980;7(2):110-4.

Reichelt A, Forster KK, Fischer M. Efficacy and safety of intramuscular glucosamine sulphate in osteoarthritis of the knee. Arzeimittel Forschung. 1994;44(1):75-80.

Hochberg MC, Clegg DO. Potential effects of chondroitin sulfate on joint swelling: A GAIT report. Osteoarthritis Cartilage. 2008;16(3):22-31.

Messier SP, Mihalko S, Loeser RF. Glucosamine/ chondroitin combined with exercise for the treatment of knee osteoarthritis: A preliminary study. Osteoarthritis Cartilage. 2007;15(11):1256-61.

Pagonis TA, Givissis PA, Kritis AC. The effect of methylsulfonylmethane on osteoarthritic large joints and mobility. Int J Orthop. 2014;1(1):19-24.

Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 2006;14(3):286-94.

Debbi EM, Agar G, Fichman G, Ziv YB, Kardosh R, Halperin N et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. BMC Complementary and Alternative Medicine. 2011;11:50.